SCHEMBL777396

SCHEMBL777396

O=S(=O)(OCF)C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.39
CA1 P00915 3/20 0.37
CA9 Q16790 1/20 0.35
CA7 P43166 1/20 0.33
CA13 Q8N1Q1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15944866 1.00 CA2 (0.39) CA2CA1CA9CA7CA13
SCHEMBL14834076 0.84 HTR1A (0.33) CA2CA1
SCHEMBL6115024 0.79 CA2 (0.41) CA2CA1CA9CA7CA13
SCHEMBL1032931 0.79 CA2 (0.47) CA2CA1CA9CA7CA13
SCHEMBL116723 0.78 CA2 (0.43) CA2CA1CA9CA7CA13
SCHEMBL12487356 0.74 CA2 (0.38) CA2CA1CA9CA7CA13
SCHEMBL1855129 0.74 CA2 (0.39) CA2CA1CA9CA7CA13
SCHEMBL47322 0.74 CA2 (0.43) CA2CA1CA9CA7CA13
SCHEMBL12506990 0.74 CA2 (0.39) CA2CA1CA9CA7CA13
SCHEMBL18238737 0.74 CA2 (0.38) CA2CA1CA9CA7CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025096782-A1 FLUORINATED CANNABINOID COMPOSITIONS AND METHODS THEREOF COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2025-05-08 WO claimed
EP-3538501-A1 RADIOLABELING AGENTS, METHODS OF MAKING, AND METHODS OF USE THEREOF The United States of America, as represented by The Secretary, Department of Health and Human Services (US) 2019-09-18 EP claimed
WO-2018144101-A1 RADIOLABELING AGENTS, METHODS OF MAKING, AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2018-08-09 WO claimed
WO-2025096782-A1 FLUORINATED CANNABINOID COMPOSITIONS AND METHODS THEREOF COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2025-05-08 WO disclosed
WO-2025090723-A1 HYDROFLUOROCARBON COMPOUNDS AND THEIR USE IN INTEGRATED CIRCUIT MANUFACTURING PROCESSES VERSUM MATERIALS US, LLC (US) 2025-05-01 WO disclosed
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 US disclosed
US-20220149436-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2022-05-12 US disclosed
US-11283107-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2022-03-22 US disclosed
US-11031626-B2 Electrolytic solution and electrochemical device containing the same NINGDE AMPEREX TECHNOLOGY LIMITED (CN) 2021-06-08 US disclosed
US-20200099101-A1 ELECTROLYTIC SOLUTION AND ELECTROCHEMICAL DEVICE CONTAINING THE SAME NINGDE AMPEREX TECHNOLOGY LIMITED (CN) 2020-03-26 US disclosed
EP-3621141-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2020-03-11 EP disclosed
US-20120177988-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2012-07-12 US disclosed
US-20120070731-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2012-03-22 US disclosed
US-20110015181-A1 ALKYLAMINOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-01-20 US disclosed
EP-2264026-A1 ALKYLAMINOPYRIDINE DERIVATIVE Banyu Pharmaceutical Co., Ltd. (JP) 2010-12-22 EP disclosed
US-20090325065-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2009-12-31 US disclosed
EP-2012386-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY Mitsubishi Chemical Corporation (JP) 2009-01-07 EP disclosed
US-7157600-B2 Process for preparing (per) fluorohalogenethers SOLVAY SOLEXIS S.P.A. (IT) 2007-01-02 US disclosed
EP-1480739-A2 APPARATUS FOR SYNTHESIS OF RADIOLABELED COMPOUNDS Bioscan, Inc. (US) 2004-12-01 EP disclosed
WO-2003064678-A2 APPARATUS FOR SYNTHESIS OF RADIOLABELED COMPOUNDS BIOSCAN, INC. (US) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015181-A1 ALKYLAMINOPYRIDINE DERIVATIVE NPY4R, NPY1R, NPY2R CA2 622/4885CA1 3676/4885CA9 2888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.